The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells
N 6 -methyladenosine (m 6 A) is an abundant nucleotide modification in mRNA that is
required for the differentiation of mouse embryonic stem cells. However, it remains unknown …
required for the differentiation of mouse embryonic stem cells. However, it remains unknown …
Molecular international prognostic scoring system for myelodysplastic syndromes
…, M Belickova, MR Savona, VM Klimek… - NEJM …, 2022 - evidence.nejm.org
Background Risk stratification and therapeutic decision-making for myelodysplastic
syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), …
syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), …
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
…, J Baselga, L Norton, S Gardos, VM Klimek… - Nature …, 2020 - nature.com
Acquired mutations are pervasive across normal tissues. However, understanding of the
processes that drive transformation of certain clones to cancer is limited. Here we study this …
processes that drive transformation of certain clones to cancer is limited. Here we study this …
[HTML][HTML] Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid …
…, EJ Feldman, GJ Schiller, VM Klimek… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Mutations leading to constitutive activation of the FMS-like tyrosine kinase 3 receptor
(FLT3) occur in blasts of 30% of patients with acute myeloid leukemia (AML). Midostaurin (…
(FLT3) occur in blasts of 30% of patients with acute myeloid leukemia (AML). Midostaurin (…
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q
…, PL Greenberg, PT Curtin, VM Klimek… - Blood, The Journal …, 2008 - ashpublications.org
Lenalidomide is approved for red blood cell (RBC) transfusion-dependent anemia due to
low or intermediate-1 (int-1) risk myelodysplastic syndromes (MDSs) associated with a …
low or intermediate-1 (int-1) risk myelodysplastic syndromes (MDSs) associated with a …
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
…, JM Bennett, VM Klimek, MR Savona, M Belickova… - Nature medicine, 2020 - nature.com
Tumor protein p53 (TP53) is the most frequently mutated gene in cancer 1 , 2 . In patients with
myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease …
myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease …
Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology
…, R Horsfall, RA Johnson, M Juckett, VM Klimek… - Journal of the National …, 2017 - jnccn.org
The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders
with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS …
with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS …
[HTML][HTML] Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
DP Steensma, M Wermke, VM Klimek, PL Greenberg… - Leukemia, 2021 - nature.com
We conducted a phase I clinical trial of H3B-8800, an oral small molecule that binds Splicing
Factor 3B1 (SF3B1), in patients with MDS, CMML, or AML. Among 84 enrolled patients (42 …
Factor 3B1 (SF3B1), in patients with MDS, CMML, or AML. Among 84 enrolled patients (42 …
[HTML][HTML] Progression of RAS-mutant leukemia during RAF inhibitor treatment
…, R Rampal, JJ Harding, VM Klimek… - … England Journal of …, 2012 - Mass Medical Soc
<p id="p001">Vemurafenib, a selective RAF inhibitor, extends survival among patients with
BRAF V600E–mutant melanoma. Vemurafenib inhibits ERK signaling in BRAF V600E–…
BRAF V600E–mutant melanoma. Vemurafenib inhibits ERK signaling in BRAF V600E–…
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled …
…, A Pigneux, HA Horst, C Recher, VM Klimek… - The lancet …, 2015 - thelancet.com
Background Safe and effective treatments are urgently needed for patients with relapsed or
refractory acute myeloid leukaemia. We investigated the efficacy and safety of vosaroxin, a …
refractory acute myeloid leukaemia. We investigated the efficacy and safety of vosaroxin, a …